Tamer A Elbedewy
Overview
Explore the profile of Tamer A Elbedewy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elsebaey M, Enaba M, Elashry H, Elbedewy T, El Nakib A, Elhadidy A, et al.
Medicina (Kaunas)
. 2024 Aug;
60(8).
PMID: 39202539
: Endoscopic biliary plastic stenting is a safe and effective temporary therapeutic modality used in various benign biliary disorders. Long-term indwelling stents for more than one year without retrieval are...
2.
Abozeid S, Elkholy R, Elbedewy T, Seliem M
J Investig Med
. 2024 Aug;
72(8):883-890.
PMID: 39092838
The etiology of vascular problems in beta-thalassemia has been linked to endothelial damage. Antiangiogenic proteins such as soluble Fms-like tyrosine kinase-1 (sFLT-1) inhibit the signaling of vascular endothelial growth factor...
3.
Elsebaey M, Elbedewy T, Elashry H, Elrefaey W, Elshweikh S, Elhadidy A, et al.
Medicine (Baltimore)
. 2022 Dec;
101(47):e31962.
PMID: 36451458
Risk of hepatitis B virus reactivation (HBVr) in patients with resolved HBV infection receiving immunosuppressive therapy has been a growing concern, particularly in the era of biological and targeted therapies....
4.
Elashtokhy H, Elgohary H, Eldeep B, Gaber S, Elbedewy T
J Egypt Natl Canc Inst
. 2021 Apr;
33(1):9.
PMID: 33826046
Background: Intensive acute lymphoblastic leukemia (ALL) regimens in children improve the 5-year event-free survival (EFS) to reach ~ 90%. Adolescents and young adults (AYA) have EFS (30% to 45%). Young...
5.
Elbedewy T, Abd-Elsalam S, Mostafa S, Abdellatif R, Fouad A, Youssef M, et al.
Endocr Metab Immune Disord Drug Targets
. 2021 Feb;
22(3):290-296.
PMID: 33530921
Background & Aims: Patients with thalassemia have a lifelong need for blood transfusion, which makes them more risky to hepatitis C virus (HCV). Iron overload and chronic HCV are considered...
6.
Elbedewy T, Elsebaey M, Elkholy R, Tahoon D, Elshweikh S
J Blood Med
. 2021 Jan;
11:533-542.
PMID: 33414648
Introduction/aim: Eltrombopag is recommended for the treatment of refractory immune thrombocytopenia (ITP). Based on its half-life, it may be practical to use an intermittent dosage. Our aim was to compare...
7.
Elbedewy T, Elashtokhy H, Abd-Elsalam S, Suliman M
Curr Cancer Drug Targets
. 2020 May;
20(8):638-645.
PMID: 32392114
Background: Egypt is one of the highest hepatitis C virus (HCV) endemic areas. Chronic HCV infection has extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is commonly...
8.
AbdelGhafar M, El-Kholy R, Elbedewy T, Allam A, Eissa R, Samy S, et al.
Gene
. 2020 Feb;
736:144419.
PMID: 32018016
Objectives: To evaluate the relationship between two common single nucleotide polymorphisms (SNPs) of CD40 gene (rs1883832 C/T and rs4810485 G/T) and the risk of immune thrombocytopenia (ITP) in the Egyptian...
9.
Elbedewy T, Elsebaey M, Elshweikh S, Elashry H, Abd-Elsalam S
Ther Clin Risk Manag
. 2019 Feb;
15:269-274.
PMID: 30804674
Background And Aims: Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is...
10.
El-Sheikh H, El-Haggar S, Elbedewy T
Diabetes Metab Syndr
. 2019 Jan;
13(1):167-173.
PMID: 30641691
Aim: Insulin resistance (IR) is predominant in type 2 diabetic patients. This study aimed to investigate benefits from adding l-carnitine to ongoing glimepiride compared to glimepiride monotherapy on IR in...